Opening New Frontiers By Advancing The Promise of PI Signaling Pathways

Steven Gillis, Ph.D.

Select a team to find out more

Steven Gillis, Ph.D.

Steven Gillis, Ph.D.

Managing Director, Arch Venture Partners

Dr. Steven Gillis joined ARCH Venture Partners in 2005. Previously, he was a founder and Director of Corixa Corp. and served as Chief Executive Officer since its inception and as Chairman from 1999 until the company was acquired in 2005 by GlaxoSmithKline.  Prior to Corixa, Steven was a founder and director of Immunex Corp. From 1981 until his departure in 1994, he served as Immunex’s Director of Research and Development, Chief Scientific Officer and Chief Executive Officer of Immunex’s research and development subsidiary.  Steven was named interim Chief Executive Officer of Immunex Corporation following its majority purchase by American Cyanamid Company and remained a member of the board until 1997.  Amgen acquired Immunex in 2002.  

Steven is an immunologist by training and has published more than 300 peer-reviewed articles and papers in the field of molecular and tumor immunology.  He is regarded as a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products, including Leukine (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20).

Steven earned a B.A. from Williams College in 1975 and received a Ph.D. in 1978 from Dartmouth College.